| 洪帆 梁江萍 秦婷婷 夏俊 徐洋.乳腺癌患者化疗后乙肝病毒再激活及拉米夫定预防性应用的临床研究[J].,2015,15(8):1505-1508 |
| 乳腺癌患者化疗后乙肝病毒再激活及拉米夫定预防性应用的临床研究 |
| Clinical Study of HBV Reactivation and Prophylactic Application ofLamivudine in Breast Cancer Patients after Chemotherapy |
| |
| DOI： |
| 中文关键词: 乳腺癌 乙型肝炎病毒 化疗 肝功能损害 HBV再激活 |
| 英文关键词: Breast cancer HBV Chemotherapy Liver function damage HBV reactivation |
| 基金项目: |
|
| 摘要点击次数: 573 |
| 全文下载次数: 800 |
| 中文摘要: |
| 目的：探讨化疗引起的乳腺癌患者肝功能损害与乙肝病毒(HBV)感染的相关性及抗病毒治疗在预防化疗引起的HBV 再激
活中的作用。方法：2006 年3 月-2010 年10 月在武汉市第三医院接受化疗的病理确诊为乳腺癌患者（包括术后辅助化疗)为研究
对象，比较HBsAg 阴性138 例和HBsAg阳性50 例患者化疗后肝功能损害的发生情况，并分析在HBsAg 阳性患者中，预防性使
用（21 例）与未预防性使用（27 例）抗病毒药物拉米夫定后乙肝病毒再激活率的差异。结果：化疗后出现肝功能损害的乳腺癌患者
中，HBsAg阳性患者（31.25%）与HBsAg阴性患者（16.67%）所占比例的差异有统计学意义(P<0.001)。化疗前预防性使用拉米夫定
（4.62%）与未预防性使用(25.93%)拉米夫定，患者出现HBV再激活率的差异亦有统计学意义(P<0.01)。结论：乳腺癌患者化疗后，
HBsAg 阳性患者较HBsAg 阴性患者更易出现肝功能损害，预防性使用核苷类似物抗病毒药物拉米夫定，可明显降低乳腺癌合并
乙肝患者化疗后HBV再激活肝炎的发生。 |
| 英文摘要: |
| Objective:To investigate the correlation between liver function damage caused by chemotherapy and hepatitis B virus
(HBV) infection in patients with breast cancer and to evaluate the effect of antiviral therapy in the prevention of chemotherapy-originated
HBV reactivation.Methods:A total of 188 breast cancer patients who were diagnosed via pathology and recieved chemotherapy,
including postoperative adjuvant chemotherapy, in the Third Hospital of Wuhan from March 2006 to October 2010 were selected as the
object of study. The post-chemotherapy liver damage situations of 138 HBsAg-negative and 50 HBsAg-positive patients were compared.
And the difference in HBV reactivation rate in HBsAg-positive patients was analyzed and compared between the group (21 cases) that
used antiviral drug lamivudine prophylacticly and the group(27 cases) which used no lamivudine.Results:The incidence of liver function
impairment after chemotherapy was 31.25%(15/48) in the HBsAg-positive patients, and 16.67%(22/132) in the HBsAg-negative patients.
The difference was statistically significant(P<0.001). In the HBsAg-positive group, the HBV reactivation rate was 4.62%(1/21) in patients
who were given prophylactic lamivudine, and was 25.93%(7/27) in patients who received no prophylactic antivirus treatment. The
difference was statistically significant (P<0.01).Conclusion:After chemotherapy, HBsAg-positive breast cancer patients are more prone
to liver function damage than HBsAg-negative patients, prophylactic use of nucleoside analogs antiviral drug lamivudine can significantly
reduce HBV reactivative hepatitis in breast cancer patients with type B hepatitis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
